Market Place
Sourcing Support
Mindwalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results
12 Mar 2026 //
BUSSINESSWIRE
Mindwalk Holdings Corp. To Release Q3 FY2026 Financial Results
02 Mar 2026 //
BUSINESSWIRE
MindWalk Breakthrough Boosts Universal Flu Program
09 Jan 2026 //
BUSINESSWIRE
Mindwalk Appoints R. Scott Areglado As CFO To Boost Growth
21 Oct 2025 //
BUSINESS WIRE
Mindwalk Appoints Dr. Thomas W. Lynch Chief Business Officer
15 Oct 2025 //
BUSINESSWIRE
Mindwalk Announces Share Repurchase Program
09 Oct 2025 //
BUSINESSWIRE
MindWalk Advances AI GLP-1 Program With Dual-Pathway Regimen
22 Sep 2025 //
BUSINESSWIRE
MindWalk Reports $7.6M Revenue, 45% Growth in Q2 Results
15 Sep 2025 //
BUSINESSWIRE
MindWalk Q1 2026 Results, Biz Highlights Coming Sept 15, 2025
10 Sep 2025 //
BUSINESSWIRE
IPA Reports Record Q4 Revenue and Adjusted EBITDA for Fiscal 2025
29 Jul 2025 //
BUSINESSWIRE
ImmunoPrecise Complies with Nasdaq Minimum Bid Price Requirement
14 Jul 2025 //
BUSINESSWIRE
ImmunoPrecise Validates LENSai Epitope Mapping Platform
03 Jul 2025 //
BUSINESSWIRE
IPA to Reschedule Q3 Financial Results to March 28, 2025
11 Mar 2025 //
BUSINESSWIRE
IPA To Report Q3 FY25 Results On March 13
05 Mar 2025 //
BUSINESSWIRE
ImmunoPrecise Antibodies Announces Key Leadership Changes
24 Feb 2025 //
BUSINESSWIRE
ImmunoPrecise Subsidiary Signs Agreement With Biotheus
02 Oct 2024 //
BUSINESSWIRE
ImmunoPrecise Reports Q4 And Full Year 2024 Results
29 Jul 2024 //
BUSINESSWIRE
ImmunoPrecise Secures $3M Convertible Debenture Financing From Yorkville
16 Jul 2024 //
BUSINESSWIRE
InterSystems and BioStrand Collab to Innovative Integration of Vector Search
28 Mar 2024 //
BUSINESSWIRE
ImmunoPrecise Antibodies Ltd. Second Quarter 2024 Earnings Release Call
27 Nov 2023 //
BUSINESSWIRE
ImmunoPrecise Reports Financial Results for Full Fiscal Year 2023
07 Jul 2023 //
BUSINESSWIRE
Talem Enters into Collaboration and License Option Agreement with Astellas
30 Mar 2023 //
BUSINESSWIRE
Talem Announces a AI-Driven Antibody Discovery Collaboration with Libera Bio
15 Mar 2023 //
BUSINESSWIRE
ImmunoPrecise Antibodies Announces Voluntary Delisting from TSX Venture Exchange
22 Nov 2022 //
BUSINESSWIRE
IPA Reports Financial Results for First Quarter Fiscal Year 2023
14 Sep 2022 //
BUSINESSWIRE
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity
14 Sep 2022 //
BUSINESSWIRE
Live Virus Assays Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants
29 Aug 2022 //
BUSINESSWIRE
ImmunoPrecise Reports Financial Results for Full Fiscal Year 2022
29 Jul 2022 //
BUSINESSWIRE
IPA to Report Financial Results for Q4 and Full FY 2022
26 Jul 2022 //
BUSINESSWIRE
Histopathology Data of PC Repeated Dose Toxicity Study and ex vivo TCR Analysis
12 Jul 2022 //
BUSINESSWIRE
IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery
14 Mar 2022 //
BUSINESSWIRE
IPA Updates on IND Enabling Program for PolyTope TATX-03
09 Mar 2022 //
BUSINESSWIRE
ImmunoPrecise Sets Q3 Fiscal 2022 Financial Results for March 16th
08 Mar 2022 //
BUSINESSWIRE
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus
18 Jan 2022 //
BUSINESSWIRE
ImmunoPrecise Antibodies Announces Grant of Stock Options
03 Jan 2022 //
BUSINESSWIRE
ImmunoPrecise, ChemPartner Collaborate for PolyTope TATX-03 Ab Manufacturing
20 Dec 2021 //
BUSINESSWIRE
ImmunoPrecise Reports Financial Results for Second Quarter Fiscal Year 2022
07 Dec 2021 //
BUSINESSWIRE
IPA Announces Resignation of Director
09 Nov 2021 //
BUSINESSWIRE
ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
13 Oct 2021 //
BUSINESSWIRE
Talem Announces Multi-Target Ab Research Collaboration With Pierre Fabre
07 Oct 2021 //
BUSINESSWIRE
ImmunoPrecise Releases Financial Statements
09 Sep 2021 //
BUSINESSWIRE
ImmunoPrecise’s Subsidiary Receives French Research Tax Credit Accreditation
08 Sep 2021 //
BUSINESSWIRE
ImmunoPrecise Announces Participation at the H.C. Wainwright Conference
07 Sep 2021 //
BUSINESSWIRE
ImmunoPrecise Reports Financial Results and Recent Business Highlights
03 Sep 2021 //
BUSINESSWIRE
ImmunoPrecise Reports Financial Results and Recent Business Highlights
03 Sep 2021 //
BUSINESSWIRE
ImmunoPrecise Reports Financial Results and Recent Main Items
30 Jul 2021 //
BUSINESS WIRE
ImmunoPrecise Reports Financial Results
29 Jul 2021 //
BUSINESSWIRE
ImmunoPrecise Reports Financial Results
29 Jul 2021 //
BUSINESSWIRE
ImmunoPrecise to Present Financial Results and Fiscal Year 2021 Highlights
15 Jul 2021 //
BUSINESS WIRE
Eurofins Discovery and ImmunoPrecise announce collaboration
23 Jun 2021 //
BUSINESSWIRE
ImmunoPrecise`s Polytope ™ Program Confirm Reduction in Lung Inflammation
17 Jun 2021 //
BUSINESSWIRE
Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program
16 Jun 2021 //
BUSINESSWIRE
ImmunoPrecise’s Drug Pipeline to be Presented at BIO International Partnering
15 Jun 2021 //
BUSINESSWIRE
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment
08 Apr 2021 //
BUSINESSWIRE
ImmunoPrecise Launches TATX-112 Candidate Antibody Program
08 Apr 2021 //
BUSINESSWIRE
ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27
16 Mar 2021 //
BUSINESSWIRE
ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27
16 Mar 2021 //
BUSINESSWIRE
ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope™
19 Feb 2021 //
BUSINESSWIRE
ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope™
19 Feb 2021 //
BUSINESSWIRE
Recombinant SARS-CoV-2 Proteins Now Available For Research From ImmunoPrecise`s
10 Jun 2020 //
PRNEWSWIRE
